Manfred Schmitt

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Specht Katja; Harbeck Nadia; Smida Jan; Annecke Katja; Reich Ulrike; Naehrig Joerg; Langer Rupert; Mages Joerg; Busch Raymonde; Kruse Elisabeth; Klein-Hitpass Ludger; Schmitt Manfred; Kiechle Marion; Hoefler Heinz
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Martens John Wm; Margossian Astrid L; Schmitt Manfred; Foekens John; Harbeck Nadia
DNA methylation as a biomarker in breast cancer.
Ruseva Zlatna; Geiger Pamina Xenia Charlotte; Hutzler Peter; Kotzsch Matthias; Luber Birgit; Schmitt Manfred; Gross Eva; Reuning Ute
Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Manfred Schmitt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Specht Katja; Harbeck Nadia; Smida Jan; Annecke Katja; Reich Ulrike; Naehrig Joerg; Langer Rupert; Mages Joerg; Busch Raymonde; Kruse Elisabeth; Klein-Hitpass Ludger; Schmitt Manfred; Kiechle Marion; Hoefler Heinz
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Breast cancer research and treatment 2009;118(1):45-56.
2009: Martens John Wm; Margossian Astrid L; Schmitt Manfred; Foekens John; Harbeck Nadia
DNA methylation as a biomarker in breast cancer.
Future oncology (London, England) 2009;5(8):1245-56.
2009: Ruseva Zlatna; Geiger Pamina Xenia Charlotte; Hutzler Peter; Kotzsch Matthias; Luber Birgit; Schmitt Manfred; Gross Eva; Reuning Ute
Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.
Experimental cell research 2009;315(10):1759-71.
2009: Schmitt Manfred; Magdolen Viktor
Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.
Thrombosis and haemostasis 2009;101(2):222-4.
2009: Duffy M J; Napieralski R; Martens J W M; Span P N; Spyratos F; Sweep F C G J; Brunner N; Foekens J A; Schmitt M;
Methylated genes as new cancer biomarkers.
European journal of cancer (Oxford, England : 1990) 2009;45(3):335-46.
2008: Diehl Peter; Schauwecker Johannes; Mittelmeier Wolfram; Schmitt Manfred
High hydrostatic pressure, a novel approach in orthopedic surgical oncology to disinfect bone, tendons and cartilage.
Anticancer research 2008;28(6B):3877-83.
2008: Weirich Gregor; Mengele Karin; Yfanti Christina; Gkazepis Apostolos; Hellmann Daniela; Welk Anita; Giersig Cecylia; Kuo Wen-Liang; Rosner Marsha Rich; Tang Wei-Jen; Schmitt Manfred
Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.
Biological chemistry 2008;389(11):1441-5.
2008: Harbeck Nadia; Nimmrich Inko; Hartmann Arndt; Ross Jeffrey S; Cufer Tanja; Grützmann Robert; Kristiansen Glen; Paradiso Angelo; Hartmann Oliver; Margossian Astrid; Martens John; Schwope Ina; Lukas Antje; Müller Volkmar; Milde-Langosch Karin; Nährig Jörg; Foekens John; Maier Sabine; Schmitt Manfred; Lesche Ralf
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5036-42.
2008: Yfanti Christina; Mengele Karin; Gkazepis Apostolos; Weirich Gregor; Giersig Cecylia; Kuo Wen-Liang; Tang Wei-Jen; Rosner Marsha; Schmitt Manfred
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.
International journal of molecular medicine 2008;22(4):421-31.
2008: Nimmrich Inko; Sieuwerts Anieta M; Meijer-van Gelder Marion E; Schwope Ina; Bolt-de Vries Joan; Harbeck Nadia; Koenig Thomas; Hartmann Oliver; Kluth Antje; Dietrich Dimo; Magdolen Viktor; Portengen Henk; Look Maxime P; Klijn Jan G M; Lesche Ralf; Schmitt Manfred; Maier Sabine; Foekens John A; Martens John W M
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Breast cancer research and treatment 2008;111(3):429-37.
2008: Stemmler Hans-Joachim; Mengele Karin; Schmitt Manfred; Harbeck Nadia; Laessig Dorit; Herrmann Karin A; Schaffer Pamela; Heinemann Volker
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Anti-cancer drugs 2008;19(8):832-6.
2008: Kotzsch Matthias; Sieuwerts Anieta M; Grosser Marianne; Meye Axel; Fuessel Susanne; Meijer-van Gelder Marion E; Smid Marcel; Schmitt Manfred; Baretton Gustavo; Luther Thomas; Magdolen Viktor; Foekens John A
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
Breast cancer research and treatment 2008;111(2):229-40.
2008: Debela Mekdes; Beaufort Nathalie; Magdolen Viktor; Schechter Norman M; Craik Charles S; Schmitt Manfred; Bode Wolfram; Goettig Peter
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
Biological chemistry 2008;389(6):623-32.
2008: Biermann Julia C; Holzscheiter Leon; Kotzsch Matthias; Luther Thomas; Kiechle-Bahat Marion; Sweep Fred C G J; Span Paul N; Schmitt Manfred; Magdolen Viktor
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
International journal of molecular medicine 2008;21(2):251-9.
2008: Beaufort Nathalie; Wojciechowski Piotr; Sommerhoff Christian P; Szmyd Grzegorz; Dubin Grzegorz; Eick Sigrun; Kellermann Josef; Schmitt Manfred; Potempa Jan; Magdolen Viktor
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin.
The Biochemical journal 2008;410(1):157-65.
2008: Knör Sebastian; Sato Sumito; Huber Timo; Morgenstern Alfred; Bruchertseifer Frank; Schmitt Manfred; Kessler Horst; Senekowitsch-Schmidtke Reingard; Magdolen Viktor; Seidl Christof
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
European journal of nuclear medicine and molecular imaging 2008;35(1):53-64.
2007: Maier Sabine; Nimmrich Inko; Koenig Thomas; Eppenberger-Castori Serenella; Bohlmann Inga; Paradiso Angelo; Spyratos Frédérique; Thomssen Christoph; Mueller Volkmar; Nährig Jörg; Schittulli Francesco; Kates Ronald; Lesche Ralf; Schwope Ina; Kluth Antje; Marx Almuth; Martens John W M; Foekens John A; Schmitt Manfred; Harbeck Nadia;
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
European journal of cancer (Oxford, England : 1990) 2007;43(11):1679-86.
2007: Sprague Lisa D; Tomaso Herbert; Mengele Karin; Schilling Daniela; Bayer Christine; Stadler Peter; Schmitt Manfred; Molls Michael
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Oncology reports 2007;17(5):1259-68.
2007: Diehl Peter; Schauwecker Johannes; Eichelberg Kay; Gollwitzer Hans; Magdolen Ursula; Gerdesmeyer Ludger; Mittelmeier Wolfram; Schmitt Manfred
Quantitative analysis of the impact of short-time high hydrostatic pressure on bone tumor-associated proteases.
International journal of molecular medicine 2007;19(4):667-73.
2007: Dorn Julia; Schmitt Manfred; Kates Ronald; Schmalfeldt Barbara; Kiechle Marion; Scorilas Andreas; Diamandis Eleftherios P; Harbeck Nadia
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1742-8.
2007: Schmitt Manfred; Mengele Karin; Schueren Elisabeth; Sweep Fred C G J; Foekens John A; Brünner Nils; Laabs Juliane; Malik Abha; Harbeck Nadia;
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.
European journal of cancer (Oxford, England : 1990) 2007;43(5):835-44.
2007: Stemmler Hans-Joachim; Schmitt Manfred; Willems Amina; Bernhard Helga; Harbeck Nadia; Heinemann Volker
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Anti-cancer drugs 2007;18(1):23-8.
2007: Radulescu Razvan T; Hufnagel Carla; Luppa Peter; Hellebrand Heide; Kuo Wen-Liang; Rosner Marsha Rich; Harbeck Nadia; Giersig Cecylia; Meindl Alfons; Schmitt Manfred; Weirich Gregor
Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.
International journal of oncology 2007;30(1):73-80.
2007: Harbeck Nadia; Schmitt Manfred; Paepke Stefan; Allgayer Heike; Kates Ronald E
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Critical reviews in clinical laboratory sciences 2007;44(2):179-201.
2006: Dorn Julia; Harbeck Nadia; Kates Ronald; Magdolen Viktor; Grass Linda; Soosaipillai Antoninus; Schmalfeldt Barbara; Diamandis Eleftherios P; Schmitt Manfred
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Biological chemistry 2006;387(8):1121-8.
2006: Diehl Peter; Steinhauser Erwin; Gollwitzer Hans; Heister Cornelia; Schauwecker Johannes; Milz Stefan; Mittelmeier Wolfram; Schmitt Manfred
Biomechanical and immunohistochemical analysis of high hydrostatic pressure-treated Achilles tendons.
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2006;11(4):380-5.
2006: Prezas Panagiotis; Arlt Matthias J E; Viktorov Petar; Soosaipillai Antoninus; Holzscheiter Leon; Schmitt Manfred; Talieri Maroulio; Diamandis Eleftherios P; Krüger Achim; Magdolen Viktor
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Biological chemistry 2006;387(6):807-11.
2006: Magdolen Ursula; Auernheimer Jörg; Dahmen Claudia; Schauwecker Johannes; Gollwitzer Hans; Tübel Jutta; Gradinger Reiner; Kessler Horst; Schmitt Manfred; Diehl Peter
Growth promoting in vitro effect of synthetic cyclic RGD-peptides on human osteoblast-like cells attached to cancellous bone.
International journal of molecular medicine 2006;17(6):1017-21.
2006: Holzscheiter Leon; Biermann Julia C; Kotzsch Matthias; Prezas Panagiotis; Farthmann Juliane; Baretton Gustavo; Luther Thomas; Tjan-Heijnen Vivianne C G; Talieri Maroulio; Schmitt Manfred; Sweep Fred C G J; Span Paul N; Magdolen Viktor
Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer.
Clinical chemistry 2006;52(6):1070-9.
2006: Stemmler H J; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Oncology reports 2006;15(5):1373-7.
2006: Foekens John A; Atkins David; Zhang Yi; Sweep Fred C G J; Harbeck Nadia; Paradiso Angelo; Cufer Tanja; Sieuwerts Anieta M; Talantov Dmitri; Span Paul N; Tjan-Heijnen Vivianne C G; Zito Alfredo F; Specht Katja; Hoefler Heinz; Golouh Rastko; Schittulli Francesco; Schmitt Manfred; Beex Louk V A M; Klijn Jan G M; Wang Yixin
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1665-71.
2006: Borgoño Carla A; Kishi Tadaaki; Scorilas Andreas; Harbeck Nadia; Dorn Julia; Schmalfeldt Barbara; Schmitt Manfred; Diamandis Eleftherios P
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1487-93.
2006: Beaufort Nathalie; Debela Mekdes; Creutzburg Sabine; Kellermann Josef; Bode Wolfram; Schmitt Manfred; Pidard Dominique; Magdolen Viktor
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Biological chemistry 2006;387(2):217-22.
2006: Schauwecker Johannes; Wirthmann Lilly; Schmitt Manfred; Tuebel Jutta; Magdolen Ursula; Gradinger Reiner; Mittelmeier Wolfram; Diehl Peter
Effect of extracorporeal high hydrostatic pressure on cellular outgrowth from tumor-afflicted bone.
Anticancer research 2006;26(1A):85-9.
2006: Sprague Lisa D; Mengele Karin; Schilling Daniela; Geurts-Moespot Anneke; Sweep Fred C G J; Stadler Peter; Schmitt Manfred; Molls Michael
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Oncology 2006;71(3-4):282-91.
2006: Schmitt Manfred; Sturmheit Alexandra S; Welk Anita; Schnelldorfer Christel; Harbeck Nadia
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Methods in molecular medicine 2006;120():245-65.
2005: Schmid I; Schmitt M; Streiter M; Meilbeck R; Haas R J; Stachel D K
Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
European journal of medical research 2005;10(11):457-61.
2005: Kotzsch Matthias; Farthmann Juliane; Meye Axel; Fuessel Susanne; Baretton Gustavo; Tjan-Heijnen Vivianne C G; Schmitt Manfred; Luther Thomas; Sweep Fred C G J; Magdolen Viktor; Span Paul N
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(17):2760-8.
2005: Krol Janna; Mengele Karin; Ottl-Mantchenko Irina; Welk Anita; Wasilewitsch Irina; von Steinburg Stephanie Pildner; Schneider Karl-Theodor M; Schmitt Manfred
Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitope.
International journal of molecular medicine 2005;16(3):415-20.
2005: Seck Katharina; Riemer Silvia; Kates Ronald; Ullrich Tobias; Lutz Verena; Harbeck Nadia; Schmitt Manfred; Kiechle Marion; Diasio Robert; Gross Eva
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5886-92.
2005: Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]
Hämostaseologie 2005;25(3):301-10.
2005: Diehl Peter; Schmitt Manfred; Schauwecker Johannes; Eichelberg Kay; Gollwitzer Hans; Gradinger Reiner; Goebel Michael; Preissner Klaus T; Mittelmeier Wolfram; Magdolen Ursula
Effect of high hydrostatic pressure on biological properties of extracellular bone matrix proteins.
International journal of molecular medicine 2005;16(2):285-9.
2005: Grebenchtchikov N; Maguire T M; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep C G J; Duffy M J
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Oncology reports 2005;14(1):235-9.
2005: Hundsdorfer Brigitte; Zeilhofer Hans-Florian; Bock Klaus Peter; Dettmar Peer; Schmitt Manfred; Kolk Andreas; Pautke Christoph; Horch Hans-Henning
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 2005;33(3):191-6.
2005: Naal Florian-Dominique; Mengele Karin; Schauwecker Johannes; Gollwitzer Hans; Gerdesmeyer Ludger; Reuning Ute; Mittelmeier Wolfram; Gradinger Reiner; Schmitt Manfred; Diehl Peter
High hydrostatic pressure-induced cell death in human chondrocytes and chondrosarcoma cells.
Anticancer research 2005;25(3B):1977-82.
2005: Martens John W M; Nimmrich Inko; Koenig Thomas; Look Maxime P; Harbeck Nadia; Model Fabian; Kluth Antje; Bolt-de Vries Joan; Sieuwerts Anieta M; Portengen Henk; Meijer-Van Gelder Marion E; Piepenbrock Christian; Olek Alexander; Höfler Heinz; Kiechle Marion; Klijn Jan G M; Schmitt Manfred; Maier Sabine; Foekens John A
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer research 2005;65(10):4101-17.
2005: Moessmer Georg; Müller Burkhardt; Kolben Martin; Schmitt Manfred; Schneider Karl Theodor Maria; Artmann Almut
HELLP syndrome with fetal growth retardation in a woman homozygous for the prothrombin gene variant 20210A.
Thrombosis and haemostasis 2005;93(4):787-8.
2005: Setyono-Han Buddy; Stürzebecher Jörg; Schmalix Wolfgang A; Muehlenweg Bernd; Sieuwerts Anieta M; Timmermans Mieke; Magdolen Viktor; Schmitt Manfred; Klijn Jan G M; Foekens John A
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Thrombosis and haemostasis 2005;93(4):779-86.
2005: Beck Veronika; Herold Hannes; Benge Anke; Luber Birgit; Hutzler Peter; Tschesche Harald; Kessler Horst; Schmitt Manfred; Geppert Harald-Gerhard; Reuning Ute
ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
The international journal of biochemistry & cell biology 2005;37(3):590-603.
2005: Del Rosso Mario; Fibbi Gabriella; Schmitt Manfred; Mignatti Paolo
Proteases and extracellular environment.
Thrombosis and haemostasis 2005;93(2):190-1.
2004: Harbeck Nadia; Kates Roanld E; Schmitt Manfred; Gauger Katja; Kiechle Marion; Janicke Fritz; Thomassen Christoph; Look Maxime P; Foekens John A
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Clinical breast cancer 2004;5(5):348-52.
2004: Werle B; Kotzsch M; Lah T T; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Anticancer research 2004;24(6):4147-61.
2004: Schmitt Manfred; Harbeck Nadia; Daidone Maria Grazia; Brynner Nils; Duffy M Joe; Foekens John A; Sweep Fred C G J
Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
International journal of oncology 2004;25(5):1397-406.
2004: Kugler Matthias Christian; Gerhard Markus; Schnelzer Andreas; Borzym Katja; Reinhardt Richard; Schmitt Manfred; Lengyel Ernst
Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome.
Gene 2004;341():189-97.
2004: Magdolen Ulla; Schroeck Florian; Creutzburg Sabine; Schmitt Manfred; Magdolen Viktor
Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1).
Biological chemistry 2004;385(9):801-8.
2004: Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Breast cancer research and treatment 2004;87(1):65-74.
2004: Diamandis Eleftherios P; Borgoño Carla A; Scorilas Andreas; Harbeck Nadia; Dorn Julia; Schmitt Manfred
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Clinical biochemistry 2004;37(9):823-9.
2004: Diehl Peter; Reuning Ute; Gollwitzer Hans; Magdolen Ulla; Gerdesmeyer Ludger; Schauwecker Johannes; Tuebel Jutta; Gradinger Reiner; Mittelmeier Wolfram; Schmitt Manfred
Effect of extracorporal high hydrostatic pressure on tumor cell adherence and viability.
Oncology reports 2004;12(2):369-73.
2004: Meijer-van Gelder Marion E; Look Maxime P; Peters Harry A; Schmitt Manfred; Brünner Nils; Harbeck Nadia; Klijn Jan G M; Foekens John A
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Cancer research 2004;64(13):4563-8.
2004: Daidone Maria Grazia; Paradiso Angelo; Gion Massimo; Harbeck Nadia; Sweep Fred; Schmitt Manfred
Biomolecular features of clinical relevance in breast cancer.
European journal of nuclear medicine and molecular imaging 2004;31 Suppl 1():S3-14.
2004: Hundsdorfer B; Zeilhofer H-F; Bock K P; Dettmar P; Schmitt M; Horch H-H
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
Mund-, Kiefer- und Gesichtschirurgie : MKG 2004;8(3):180-90.
2004: Hundsdorfer B; Zeilhofer H-F; Bock K P; Dettmar P; Schmitt M; Horch H-H
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
Mund-, Kiefer- und Gesichtschirurgie : MKG 2004;8(3):173-9.
2004: Diehl Peter; Hantke Bernd; Hennig Michael; Tschesche Harald; Mittelmeier Wolfram; Schmitt Manfred; Muehlenweg Bernd
Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
International journal of molecular medicine 2004;13(5):711-5.
2004: Harbeck Nadia; Kates Ronald E; Gauger Katja; Willems Amina; Kiechle Marion; Magdolen Viktor; Schmitt Manfred
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Thrombosis and haemostasis 2004;91(3):450-6.
2004: Scorilas Andreas; Borgoño Carla A; Harbeck Nadia; Dorn Julia; Schmalfeldt Barbara; Schmitt Manfred; Diamandis Eleftherios P
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):678-85.
2004: Bader R; Steinhauser E; Holzwarth U; Schmitt M; Mittelmeier W
A novel test method for evaluation of the abrasive wear behaviour of total hip stems at the interface between implant surface and bone cement.
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2004;218(4):223-30.
2003: Gross Eva; Ullrich Tobias; Seck Katharina; Mueller Volkmar; de Wit Maike; von Schilling Christoph; Meindl Alfons; Schmitt Manfred; Kiechle Marion
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Human mutation 2003;22(6):498.
2003: Sweep Fred C G J; Fritsche Herbert A; Gion Massimo; Klee George G; Schmitt Manfred;
Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
International journal of oncology 2003;23(6):1715-26.
2003: Diamandis Eleftherios P; Borgoño Carla A; Scorilas Andreas; Yousef George M; Harbeck Nadia; Dorn Julia; Schmalfeldt Barbara; Schmitt Manfred
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(6):299-309.
2003: Diehl Peter; Schmitt Manfred; Blümelhuber Gerrit; Frey Benjamin; Van Laak Susanne; Fischer Steffen; Muehlenweg Bernd; Meyer-Pittroff Roland; Gollwitzer Hans; Mittelmeier Wolfram
Induction of tumor cell death by high hydrostatic pressure as a novel supporting technique in orthopedic surgery.
Oncology reports 2003;10(6):1851-5.
2003: Hantke Bernd; Harbeck Nadia; Schmalfeldt Barbara; Claes Ingeborg; Hiller Oliver; Luther Marc-Oliver; Welk Anita; Kuhn Walther; Schmitt Manfred; Tschesche Harald; Muehlenweg Bernd
Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Biological chemistry 2003;384(8):1247-51.
2003: Reuning Ute; Magdolen Viktor; Hapke Sandra; Schmitt Manfred
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Biological chemistry 2003;384(8):1119-31.
2003: Krol Janna; Kopitz Charlotte; Kirschenhofer Angela; Schmitt Manfred; Magdolen Ulla; Krüger Achim; Magdolen Viktor
Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Biological chemistry 2003;384(7):1097-102.
2003: Krol Janna; Sato Sumito; Rettenberger Peter; Assfalg-Machleidt Irmgard; Schmitt Manfred; Magdolen Viktor; Magdolen Ulla
Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Biological chemistry 2003;384(7):1085-96.
2003: Hapke Sandra; Kessler Horst; Luber Birgit; Benge Anke; Hutzler Peter; Höfler Heinz; Schmitt Manfred; Reuning Ute
Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.
Biological chemistry 2003;384(7):1073-83.
2003: Yousef George M; Polymeris Mary-Ellen; Grass Linda; Soosaipillai Antoninus; Chan Pak-Cheung; Scorilas Andreas; Borgoño Carla; Harbeck Nadia; Schmalfeldt Barbara; Dorn Julia; Schmitt Manfred; Diamandis Eleftherios P
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Cancer research 2003;63(14):3958-65.
2003: Schrohl Anne-Sofie; Holten-Andersen Mads; Sweep Fred; Schmitt Manfred; Harbeck Nadia; Foekens John; Brünner Nils;
Tumor markers: from laboratory to clinical utility.
Molecular & cellular proteomics : MCP 2003;2(6):378-87.
2003: Kishi Tadaaki; Grass Linda; Soosaipillai Antoninus; Scorilas Andreas; Harbeck Nadia; Schmalfeldt Barbara; Dorn Julia; Mysliwiec Michal; Schmitt Manfred; Diamandis Eleftherios P
Human kallikrein 8, a novel biomarker for ovarian carcinoma.
Cancer research 2003;63(11):2771-4.
2003: Luther Thomas; Kotzsch Matthias; Meye Axel; Langerholc Thomaz; Füssel Susanne; Olbricht Natalie; Albrecht Sybille; Ockert Detlev; Muehlenweg Bernd; Friedrich Katrin; Grosser Marianne; Schmitt Manfred; Baretton Gustavo; Magdolen Viktor
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Thrombosis and haemostasis 2003;89(4):705-17.
2003: Schmitt Manfred; Magdolen Viktor; Reuning Ute
Theme Issue: update on the role of the fibrinolysis/plasminogen activation system in a cellular context.
Thrombosis and haemostasis 2003;89(4):596-8.
2003: Zemzoum Iris; Kates Ronald E; Ross Jeffrey S; Dettmar Peer; Dutta Moshumi; Henrichs Cordula; Yurdseven Suna; Höfler Heinz; Kiechle Marion; Schmitt Manfred; Harbeck Nadia
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1022-8.
2003: Reuning Ute; Sperl Stefan; Kopitz Charlotte; Kessler Horst; Krüger Achim; Schmitt Manfred; Magdolen Viktor
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Current pharmaceutical design 2003;9(19):1529-43.
2003: Kates Ronald; Schmitt Manfred; Harbeck Nadia
Advanced statistical methods for the definition of new staging models.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():101-13.
2003: Roggel Frigga; Hocke Stefan; Lindemann Kristina; Sinz Sonja; Welk Anita; Bosl Martin; Pabst Martina; Nusser N; Braun Stephan; Schmitt Manfred; Harbeck Nadia
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():89-100.
2003: Magdolen Viktor; Krüger Achim; Sato Sumito; Nagel Jutta; Sperl Stefan; Reuning Ute; Rettenberger Peter; Magdolen Ulla; Schmitt Manfred
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():43-63.
2003: Guthaus Elke; Schmiedeberg Niko; Bürgle Markus; Magdolen Viktor; Kessler Horst; Schmitt Manfred
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():3-14.
2002: Schmiedeberg Niko; Schmitt Manfred; Rölz Christian; Truffault Vincent; Sukopp Martin; Bürgle Markus; Wilhelm Olaf G; Schmalix Wolfgang; Magdolen Viktor; Kessler Horst
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Journal of medicinal chemistry 2002;45(23):4984-94.
2002: Sato Sumito; Kopitz Charlotte; Schmalix Wolfgang A; Muehlenweg Bernd; Kessler Horst; Schmitt Manfred; Krüger Achim; Magdolen Viktor
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
FEBS letters 2002;528(1-3):212-6.
2002: Harbeck Nadia; Schmitt Manfred; Kates Ronald E; Kiechle Marion; Zemzoum Iris; Jänicke Fritz; Thomssen Christoph
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical breast cancer 2002;3(3):196-200.
2002: Harbeck Nadia; Kates Ronald E; Look Maxime P; Meijer-Van Gelder Marion E; Klijn Jan G M; Krüger Achim; Kiechle Marion; Jänicke Fritz; Schmitt Manfred; Foekens John A
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer research 2002;62(16):4617-22.
2002: Schroeck Florian; Arroyo de Prada Nuria; Sperl Stefan; Schmitt Manfred; Viktor Magdolen
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Biological chemistry 2002;383(7-8):1143-9.
2002: Schmid I; Stachel D K; Freudenberg S; Schmitt M; Schuster F; Haas R J
Megestrol acetate to correct the nutritional status in an adolescent with growth hormone deficiency: Increase of appetite and body weight but only by increase of body water and fat mass followed by profound cortisol and testosterone depletion.
Klinische Pädiatrie 2002;214(2):54-7.
2002: Harbeck Nadia; Kates Ronald E; Schmitt Manfred
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):1000-7.
2002: Bange Johannes; Prechtl Dieter; Cheburkin Yuri; Specht Katja; Harbeck Nadia; Schmitt Manfred; Knyazeva Tatjana; Müller Susanne; Gärtner Silvia; Sures Irmi; Wang Hongyang; Imyanitov Evgeny; Häring Hans-Ulrich; Knayzev Pjotr; Iacobelli Stefano; Höfler Heinz; Ullrich Axel
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Cancer research 2002;62(3):840-7.
2002: Guthaus Elke; Bürgle Markus; Schmiedeberg Niko; Hocke Stefan; Eickler Alexandra; Kramer Michael D; Sweep C G J Fred; Magdolen Viktor; Kessler Horst; Schmitt Manfred
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Biological chemistry 2002;383(1):207-16.
2002: Del Rosso Mario; Fibbi Gabriella; Schmitt Manfred
Non-enzymatic activities of proteases: from scepticism to reality.
Biological chemistry 2002;383(1):1-4.
2002: Arroyo De Prada Nuria; Schroeck Florian; Sinner Eva-Kathrin; Muehlenweg Bernd; Twellmeyer Jens; Sperl Stefan; Wilhelm Olaf G; Schmitt Manfred; Magdolen Viktor
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
European journal of biochemistry / FEBS 2002;269(1):184-92.
2002: Janz Martin; Harbeck Nadia; Dettmar Peer; Berger Ursula; Schmidt Anja; Jürchott Karsten; Schmitt Manfred; Royer Hans-Dieter
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
International journal of cancer. Journal international du cancer 2002;97(3):278-82.
2002: Schindlbeck C; Janni W; Schaffer P; Shabani N; Schmitt M; Harbeck N; Sommer H; Braun S
[Tumor biology of primary breast cancer and minimal residual disease]
Acta medica Austriaca. Supplement 2002;59():27-31.
2001: Schmitt M
International Proteolysis Society in association with the International Conference on Protease Inhibitors--second general meeting.
IDrugs : the investigational drugs journal 2001;4(12):1361-4.
2001: Sperl S; Mueller M M; Wilhelm O G; Schmitt M; Magdolen V; Moroder L
The uPA/uPA receptor system as a target for tumor therapy.
Drug news & perspectives 2001;14(7):401-11.
2001: Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates R E; Schmitt M
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2757-64.
2001: Magdolen V; Bürgle M; de Prada N A; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm O G; Schmitt M; Kessler H
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Biological chemistry 2001;382(8):1197-205.
2001: Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Gynecologic oncology 2001;82(2):291-8.
2001: Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2396-404.
2001: Muehlenweg B; Sperl S; Magdolen V; Schmitt M; Harbeck N
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Expert opinion on biological therapy 2001;1(4):683-91.
2001: Hapke S; Kessler H; Arroyo de Prada N; Benge A; Schmitt M; Lengyel E; Reuning U
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
The Journal of biological chemistry 2001;276(28):26340-8.
2001: Harbeck N; Krüger A; Sinz S; Kates R E; Thomssen C; Schmitt M; Jänicke F
Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Onkologie 2001;24(3):238-44.
2001: Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep C G; Selbmann H K; Graeff H; Schmitt M;
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Journal of the National Cancer Institute 2001;93(12):913-20.
2001: Lutz V; Reuning U; Krüger A; Luther T; von Steinburg S P; Graeff H; Schmitt M; Wilhelm O G; Magdolen V
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Biological chemistry 2001;382(5):789-98.
2001: Hapke S; Gawaz M; Dehne K; Köhler J; Marshall J F; Graeff H; Schmitt M; Reuning U; Lengyel E
beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.
Molecular and cellular biology 2001;21(6):2118-32.
2001: Krüger A; Soeltl R; Sopov I; Kopitz C; Arlt M; Magdolen V; Harbeck N; Gänsbacher B; Schmitt M
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
Cancer research 2001;61(4):1272-5.
2001: Lengyel E; Ried S; Heiss M M; Jäger C; Schmitt M; Allgayer H
Ras regulation of urokinase-type plasminogen activator.
Methods in enzymology 2001;333():105-16.
2000: Hannke-Lohmann A; Pildner von Steinburg S; Dehne K; Benard V; Kolben M; Schmitt M; Lengyel E
Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.
Obstetrics and gynecology 2000;96(4):582-7.
2000: Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer M D; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
International journal of oncology 2000;17(4):827-34.
2000: Muehlenweg B; Assfalg-Machleidt I; Parrado S G; Bürgle M; Creutzburg S; Schmitt M; Auerswald E A; Machleidt W; Magdolen V
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
The Journal of biological chemistry 2000;275(43):33562-6.
2000: Stadler P; Feldmann H J; Creighton C; Zeilhoffer H F; Zimmermann V; Schmitt M; Molls M
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
The International journal of biological markers 2000;15(3):235-6.
2000: Kowolik J H; Kuhn W; Nährig J; Werner M; Obst T; Avril N; Schmitt M; Graeff H
Detection of micrometastases in sentinel lymph nodes of the breast applying monoclonal antibodies AE1/AE3 to pancytokeratins.
Oncology reports 2000;7(4):745-9.
2000: Schnelzer A; Prechtel D; Knaus U; Dehne K; Gerhard M; Graeff H; Harbeck N; Schmitt M; Lengyel E
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
Oncogene 2000;19(26):3013-20.
2000: Hildenbrand R; Leitz M; Magdolen V; Luther T; Albrecht S; Graeff H; Stutte H J; Bleyl U; Schmitt M
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Histopathology 2000;36(6):499-504.
2000: Muehlenweg B; Guthaus E; de Prada N A; Schmitt M; Schmiedeberg N; Kotzsch M; Creutzburg S; Kramer M D; Kessler H; Wilhelm O G; Magdolen V
Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.
Thrombosis research 2000;98(1):73-81.
2000: Krüger A; Soeltl R; Lutz V; Wilhelm O G; Magdolen V; Rojo E E; Hantzopoulos P A; Graeff H; Gänsbacher B; Schmitt M
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Cancer gene therapy 2000;7(2):292-9.
2000: Foekens J A; Peters H A; Look M P; Portengen H; Schmitt M; Kramer M D; Brünner N; Jänicke F; Meijer-van Gelder M E; Henzen-Logmans S C; van Putten W L; Klijn J G
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Cancer research 2000;60(3):636-43.
2000: Harbeck N; Kates R; Ulm K; Graeff H; Schmitt M
Neural network analysis of follow-up data in primary breast cancer.
The International journal of biological markers 2000;15(1):116-22.
2000: Noack F; Schmitt M; Bauer J; Helmecke D; Krüger W; Thorban S; Sandherr M; Kuhn W; Graeff H; Harbeck N
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
The International journal of biological markers 2000;15(1):100-4.
2000: Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
The International journal of biological markers 2000;15(1):79-83.
2000: Prechtl A; Harbeck N; Thomssen C; Meisner C; Braun M; Untch M; Wieland M; Lisboa B; Cufer T; Graeff H; Selbmann K; Schmitt M; Jänicke F
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
The International journal of biological markers 2000;15(1):73-8.
2000: Magdolen V; Arroyo de Prada N; Sperl S; Muehlenweg B; Luther T; Wilhelm O G; Magdolen U; Graeff H; Reuning U; Schmitt M
Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.
Advances in experimental medicine and biology 2000;477():331-41.
1999: Noack F; Helmecke D; Rosenberg R; Thorban S; Nekarda H; Fink U; Lewald J; Stich M; Schutze K; Harbeck N; Magdolen V; Graeff H; Schmitt M
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
International journal of oncology 1999;15(4):617-23.
1999: Della Porta P; Soeltl R; Krell H W; Collins K; O'Donoghue M; Schmitt M; Krüger A
Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Anticancer research 1999;19(5B):3809-16.
1999: Wilhelm O G; Wilhelm S; Escott G M; Lutz V; Magdolen V; Schmitt M; Rifkin D B; Wilson E L; Graeff H; Brunner G
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.
Journal of cellular physiology 1999;180(2):225-35.
1999: Ried S; Jäger C; Jeffers M; Vande Woude G F; Graeff H; Schmitt M; Lengyel E
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
The Journal of biological chemistry 1999;274(23):16377-86.
1999: Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
British journal of cancer 1999;80(3-4):419-26.
1999: Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
British journal of cancer 1999;79(11-12):1746-51.
1999: Harbeck N; Ross J S; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
International journal of oncology 1999;14(4):663-71.
1999: Harbeck N; Thomssen C; Berger U; Ulm K; Kates R E; Höfler H; Jänicke F; Graeff H; Schmitt M
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Breast cancer research and treatment 1999;54(2):147-57.
1999: Reuning U; Guerrini L; Nishiguchi T; Page S; Seibold H; Magdolen V; Graeff H; Schmitt M
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
European journal of biochemistry / FEBS 1999;259(1-2):143-8.
1999: Schmitt M; Kuhn W; Harbeck N; Graeff H
Thrombophilic state in breast cancer.
Seminars in thrombosis and hemostasis 1999;25(2):157-66.
1998: Sweep C G; Geurts-Moespot J; Grebenschikov N; de Witte J H; Heuvel J J; Schmitt M; Duffy M J; Jänicke F; Kramer M D; Foekens J A; Brünner N; Brugal G; Pedersen A N; Benraad T J
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
British journal of cancer 1998;78(11):1434-41.
1998: Reuning U; Magdolen V; Wilhelm O; Fischer K; Lutz V; Graeff H; Schmitt M
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
International journal of oncology 1998;13(5):893-906.
1998: Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
FEBS letters 1998;438(1-2):101-5.
1998: Wilhelm S; Schmitt M; Parkinson J; Kuhn W; Graeff H; Wilhelm O G
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
International journal of oncology 1998;13(4):645-51.
1998: Eppenberger U; Kueng W; Schlaeppi J M; Roesel J L; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens J A; Eppenberger-Castori S
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3129-36.
1998: Ruiter D J; Ferrier C M; van Muijen G N; Henzen-Logmans S C; Kennedy S; Kramer M D; Nielsen B S; Schmitt M
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1334-40.
1998: Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte H J; Schmitt M
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Histochemistry and cell biology 1998;110(1):27-32.
1998: Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller J D; Fink U; Siewert J R
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1755-63.
1998: Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Anticancer research 1998;18(3C):2187-97.
1998: Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Anticancer research 1998;18(3C):2173-80.
1998: Magdolen V; Albrecht S; Kotzsch M; Haller C; Bürgle M; Jacob U; Grosser M; Kessler H; Graeff H; Müller M; Schmitt M; Luther T
Immunological and functional analyses of the extracellular domain of human tissue factor.
Biological chemistry 1998;379(2):157-65.
1998: Stephens R W; Brünner N; Jänicke F; Schmitt M
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
Breast cancer research and treatment 1998;52(1-3):99-111.
1997: Laugwitz K L; Kronsbein K; Schmitt M; Hoffmann K; Seyfarth M; Schömig A; Ungerer M
Characterization and inhibition of beta-adrenergic receptor kinase in intact myocytes.
Cardiovascular research 1997;35(2):324-33.
1997: Köhler U; Hiller K; Martin R; Langanke D; Naumann G; Bilek K; Jänicke F; Schmitt M
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Gynecologic oncology 1997;66(2):268-74.
1997: Schmitt M; Harbeck N; Thomssen C; Wilhelm O; Magdolen V; Reuning U; Ulm K; Höfler H; Jänicke F; Graeff H
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Thrombosis and haemostasis 1997;78(1):285-96.
1997: Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Electrophoresis 1997;18(5):686-9.
1997: Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
The American journal of pathology 1997;150(4):1231-44.
1997: Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle U H; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Biological chemistry 1997;378(3-4):231-7.
1997: Kolben M; Bläser J; Ulm K; Schmitt M; Schneider K T; Tschesche H; Graeff H
Angiogenin plasma levels during pregnancy.
American journal of obstetrics and gynecology 1997;176(1 Pt 1):37-41.
1997: Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
British journal of cancer 1997;76(3):306-11.
1997: Dettmar P; Harbeck N; Thomssen C; Pache L; Ziffer P; Fizi K; Jänicke F; Nathrath W; Schmitt M; Graeff H; Höfler H
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.
British journal of cancer 1997;75(10):1525-33.
1996: Kolben M; Lopens A; Bläser J; Ulm K; Schmitt M; Schneider K T; Tschesche H
Proteases and their inhibitors are indicative in gestational disease.
European journal of obstetrics, gynecology, and reproductive biology 1996;68(1-2):59-65.
1996: Ott I; Neumann F J; Gawaz M; Schmitt M; Schömig A
Increased neutrophil-platelet adhesion in patients with unstable angina.
Circulation 1996;94(6):1239-46.
1996: Benraad T J; Geurts-Moespot J; Grøndahl-Hansen J; Schmitt M; Heuvel J J; de Witte J H; Foekens J A; Leake R E; Brünner N; Sweep C G
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1371-81.
1996: Wagner S N; Atkinson M J; Thanner S; Schmitt M; Wilhelm O; Rotter M; Höfler H
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
The Journal of pathology 1996;179(1):95-9.
1996: Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle U H; König B; Graeff H; Schmitt M; Wilhelm O
Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1996;237(3):743-51.
1996: Wagner S N; Atkinson M J; Wagner C; Höfler H; Schmitt M; Wilhelm O
Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.
Histochemistry and cell biology 1996;105(1):53-60.
1995: Reuning U; Wilhelm O; Nishiguchi T; Guerrini L; Blasi F; Graeff H; Schmitt M
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Nucleic acids research 1995;23(19):3887-93.
1995: Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Cancer research 1995;55(18):3958-63.
1995: Triebel S; Bläser J; Gote T; Pelz G; Schüren E; Schmitt M; Tschesche H
Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes.
European journal of biochemistry / FEBS 1995;231(3):714-9.
1995: Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(7):741-6.
1995: Wilhelm O; Schmitt M; Höhl S; Senekowitsch R; Graeff H
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.
Clinical & experimental metastasis 1995;13(4):296-302.
1995: Wagner S N; Atkinson M J; Thanner S; Wagner C; Schmitt M; Wilhelm O; Rotter M; Höfler H
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
The American journal of pathology 1995;147(1):183-92.
1995: Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Journal of obstetrics and gynaecology (Tokyo, Japan) 1995;21(2):151-65.
1995: Magdolen U; Magdolen V; Schmitt M; Bandlow W
Selection of specific gene probes by combined use of low-stringency PCR amplification and Southern-blot hybridization.
Current genetics 1995;27(4):390-2.
1995: Harbeck N; Dettmar P; Thomssen Ch; Pache L; Ziffer P; Fizi K; Jänicke F; Nathrath W; Schmitt M; Graeff H
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma]
Gynäkologisch-geburtshilfliche Rundschau 1995;35 Suppl 1():142-7.
1994: Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Gynecologic oncology 1994;55(3 Pt 1):401-9.
1994: Wilhelm S; Wilhelm O; Schmitt M; Graeff H
Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
Biological chemistry Hoppe-Seyler 1994;375(9):603-8.
1994: Foekens J A; Schmitt M; van Putten W L; Peters H A; Kramer M D; Jänicke F; Klijn J G
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1648-58.
1994: Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder J D; Fink U; Siewert J R
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Cancer research 1994;54(11):2900-7.
1994: Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Cancer research 1994;54(10):2527-30.
1994: Kolben M; Lopens A; Schmitt M; Schneider K T; Graeff H
[Changes in fibrinolysis-associated parameters in HELLP syndrome]
Geburtshilfe und Frauenheilkunde 1994;54(5):257-61.
1994: McGahon A; Bissonnette R; Schmitt M; Cotter K M; Green D R; Cotter T G
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
Blood 1994;83(5):1179-87.
1994: Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
FEBS letters 1994;337(2):131-4.
1994: Nekarda H; Siewert J R; Schmitt M; Ulm K
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.
Lancet 1994;343(8889):117.
1993: Pedersen N; Schmitt M; Rønne E; Nicoletti M I; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
The Journal of clinical investigation 1993;92(5):2160-7.
1993: Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
British journal of cancer 1993;67(3):537-44.
1993: Harbeck N; Schüren E; Yamamoto N; Pache L; Schmitt M; Jänicke F; Dettmar P; Höfler H; Graeff H
[DNA flow cytometric analysis in primary breast cancer. S-phase and ploidy status as prognostic factors and their correlation to tumor-associated proteolytic factors]
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():303-4.
1993: Harbeck N; Schüren E; Yamamoto N; Schmitt M; Höfler H; Graeff H
[Development of a technique for isolation of intact tumor cells from fresh breast or ovarian cancer tissue. Use in analysis of tumor-associated proteolytic factors]
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():277-9.
1993: Wilhelm S; Wilhelm O; Schmitt M; Möbus V; Kreienberg R; Graeff H
[Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells]
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():202-3.
1993: Graeff H; Wilhelm O; Jänicke F; Schmitt M
[Tumor biology-oriented treatment concepts]
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():193-6.
1992: Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Biological chemistry Hoppe-Seyler 1992;373(7):611-22.
1992: Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler W A; Jänicke F; Graeff H
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
FEBS letters 1992;297(1-2):112-8.
1992: Chucholowski N; Schmitt M; Goretzki L; Schüren E; Moniwa N; Weidle U; Kramer M; Wagner B; Jänicke F; Graeff H
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Biochemical Society transactions 1992;20(1):208-16.
1991: Jänicke F; Schmitt M; Graeff H
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Seminars in thrombosis and hemostasis 1991;17(3):303-12.
1991: Schmitt M; Chucholowski N; Busch E; Hellmann D; Wagner B; Goretzki L; Jänicke F; Günzler W A; Graeff H
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Seminars in thrombosis and hemostasis 1991;17(3):291-302.
1991: Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler W A; Jänicke F; Graeff H
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
The Journal of biological chemistry 1991;266(8):5147-52.
1991: Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Advances in experimental medicine and biology 1991;297():111-28.
1991: Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Biomedica biochimica acta 1991;50(4-6):731-41.
1990: Schmitt M; Bültmann B
Fluorescent chemotactic peptides as tools to identify the f-Met-Leu-Phe receptor on human granulocytes.
Biochemical Society transactions 1990;18(2):219-22.
1990: Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Blood 1990;75(8):1673-8.
1989: Jänicke F; Schmitt M; Ulm K; Gössner W; Graeff H
Urokinase-type plasminogen activator antigen and early relapse in breast cancer.
Lancet 1989;2(8670):1049.
1989: Schmitt M; Kanayama N; Henschen A; Hollrieder A; Hafter R; Gulba D; Jänicke F; Graeff H
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
FEBS letters 1989;255(1):83-8.
1988: Wilhelm O; Hafter R; Coppenrath E; Pflanz M A; Schmitt M; Babic R; Linke R; Gössner W; Graeff H
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma.
Cancer research 1988;48(12):3507-14.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Manfred Schmitt

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Manfred Schmitt (preview)

All Publications